CS-2394
CS-2394 性质
| 密度 | 1.51±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | -20°C |
| 溶解度 | 不溶于水；不溶于乙醇；不溶于DMSO |
| 酸度系数(pKa) | 9.01±0.70(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至浅棕色 |
| InChI | 1S/C23H20N4O3S3/c1-13-7-8-14-18(11-13)33-22(24-14)26-19(28)12-32-23-25-15-9-10-31-20(15)21(29)27(23)16-5-3-4-6-17(16)30-2/h3-8,11H,9-10,12H2,1-2H3,(H,24,26,28) |
| InChIKey | RHUJMHOIQBDFQR-UHFFFAOYSA-N |
| SMILES | O=C1C2=C(CCS2)N=C(SCC(NC3=NC(C=CC(C)=C4)=C4S3)=O)N1C5=C(OC)C=CC=C5 |
CS-2394 用途与合成方法
IC50: 25 nM (Wnt)
IWP-4 is a small molecule Wnt inhibitor with an IC 50 of 25 nM. IWP-4 induces the expression of cardiac markers, including cardiac troponin I (CTNI) and cardiac myosin heavy chain bright cells (MYH hi + ). IWP-4 also results in the appearance of beating foci (0.44±0.10 SEM beats per second), which is absent in all cultures not receiving IWP-4. Further, flow cytometric analysis shows that there are significantly more MYH lo + cells in IWP-4 treated cultures (P<0.0002) compare with untreated cultures at day 16, being 17.0±1.3 SD% and 5.4±1.4 SD%, respectively. Quantification of NKX2-5 protein expression shows that 63% (481/817) of IWP-4 treated cells display nuclear NKX2-5 expression. Mesenchymal precursor cells (MPCs) treated with IWP-4 show no significant changes in the expression of AXIN2 , CTNNB1 and GSK3B as compare to osteogenic medium alone on day 7, but MPCs treated with IWP-4 express elevates levels of DKK1 and GSK3β on day 21. IWP-4 also causes a significant down regulation of SPARC and COL1A1 .
CS-2394 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-12879 | 686772-17-8 | 1 mg | 411 | |
| 2025-12-22 | HY-12879 | CS-2394 | 686772-17-8 | 5mg | 1500 |
